The company is diversifying its portfolio with drugs targeting obesity, diabetes, and other conditions, aiming to impact 1 billion people
People werent getting off the drugs and the costs were skyrocketing. Benefits manager, large retailer We cover for Wegovy, but the health insurance has notified us that they will no longer be doing that
Check ingredients for allergies and follow package directions
We assessed glycemic control, body weight and composition (with bio-impedance analysis), liver fibrosis and steatosis (with transient elastography)
What started as a therapeutic class focused primarily on type 2 diabetes management has now evolved into a powerful, sustained, evidence-based solution for obesity and weight reduction- a disease in its own right
- [DOI] [PubMed] [Google Scholar] 33.Holmes BB, Diamond MI